Kenneth Nahum

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Ignace Vergote, Giovanni Scambia, David M. O’Malley et al. · The Lancet Oncology · 2019 · 86 citations · Full text

Medicine, Gynecology, Oncology +11

BLT-D (Clarithromycin [Biaxin], Low-Dose Thalidomide, and Dexamethasone) for the Treatment of Myeloma and Waldenström's Macroglobulinemia

Morton Coleman, John P. Leonard, Larry Lyons et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2002 · 79 citations

Medicine, Pharmacology, Pharmacotherapy +13

A Multi-institutional Phase 2 Study of Imatinib Mesylate and Gemcitabine for First-Line Treatment of Advanced Pancreatic Cancer.

Rebecca A. Moss, Mary F. Mulcahy, Kenneth Nahum et al. · PubMed · 2012 · 19 citations · Full text

Medicine, Oncology, Pharmacology +15

A Case of Pneumatosis Intestinalis With Pneumoperitoneum as a Potential Delayed Adverse Effect of Capecitabine

Taimoor Khan, Mujtaba Mohamed, Kenneth Nahum et al. · World Journal of Oncology · 2019 · 13 citations · Full text

Medicine, Oncology, Pharmacology +15